New drug shows promise for alcohol hepatitis in early trial
NCT ID NCT06685692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called ADX-629 in 4 adults with moderate alcohol-related hepatitis. The goal was to see if the drug is safe and can help control liver inflammation. Participants had to stop drinking alcohol during the trial. The study is now complete, and results will show whether the drug is worth testing in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bon Secours Liver Institute of Newport News
Richmond, Virginia, 23221, United States
-
Florida Health Sciences Center/Tampa General Hospital/USF
Tampa, Florida, 33606, United States
-
Methodist Specialty and Transplant Hospital
San Antonio, Texas, 78229, United States
-
Synergry Healthcare
Bradenton, Florida, 34209, United States
-
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas, 75203, United States
-
UDL Clinical Research, LLC
Houston, Texas, 77057, United States